These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32113619)

  • 1. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
    Kaltenboeck A
    Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting.
    Swart ECS; Parekh N; Daw J; Manolis C; Good CB; Neilson LM
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1385-1389. PubMed ID: 33119437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
    Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value-based Healthcare: The Politics of Value-based Care and its Impact on Orthopaedic Surgery.
    Lin E; Sage WM; Bozic KJ; Jayakumar P
    Clin Orthop Relat Res; 2021 Apr; 479(4):674-678. PubMed ID: 33704105
    [No Abstract]   [Full Text] [Related]  

  • 7. [Price of medications: the actual system must be seen again].
    Mayencourt J
    Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613
    [No Abstract]   [Full Text] [Related]  

  • 8. Specific Value Assessment Considerations.
    Kamal-Bahl S; Towse A; Spurgin L; Danzon PM
    Value Health; 2019 Jun; 22(6S):S24-S28. PubMed ID: 31200803
    [No Abstract]   [Full Text] [Related]  

  • 9. Current Policy and Practice for Value-Based Pricing.
    Augustovski F; McClellan MB
    Value Health; 2019 Jun; 22(6S):S4-S6. PubMed ID: 31200805
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending?
    Seeley E; Kesselheim AS
    Issue Brief (Commonw Fund); 2017 Sep; 2017():1-8. PubMed ID: 28953345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare-An Introduction.
    Willke RJ
    Value Health; 2019 Jun; 22(6S):S1-S3. PubMed ID: 31200800
    [No Abstract]   [Full Text] [Related]  

  • 12. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
    Ludwig S; Dintsios CM
    Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative's Prior Authorization Learning Collaborative.
    Psotka MA; Singletary EA; Bleser WK; Roiland RA; Hamilton Lopez M; Saunders RS; Wang TY; McClellan MB; Brown N;
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006564. PubMed ID: 32683983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.
    Morgan S; Daw J; Thomson P
    Health Aff (Millwood); 2013 Apr; 32(4):771-7. PubMed ID: 23569058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing Value-Based Cardiovascular Care: The American Heart Association Value in Healthcare Initiative.
    McClellan MB; Bleser WK; Joynt Maddox KE
    Circ Cardiovasc Qual Outcomes; 2020 May; 13(5):e006610. PubMed ID: 32393127
    [No Abstract]   [Full Text] [Related]  

  • 19. Current Value Frameworks-What's New?
    Willke RJ; Chapman RH; Seidman JJ; Schnipper LE; Gleason PP
    Value Health; 2019 Jun; 22(6S):S7-S11. PubMed ID: 31200806
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical Next Steps in Improving Value Measurement and Use.
    Ollendorf DA; Kamal-Bahl S; Gleason PP; Schrandt S; McElwee N
    Value Health; 2019 Jun; 22(6S):S29-S31. PubMed ID: 31200804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.